| Name | Title | Contact Details |
|---|
Savista is a prominent provider of healthcare revenue cycle management services. Savista partners with healthcare organizations to problem solve and deliver revenue cycle improvement services that enable their success, support their patients, and nurture their communities. We integrate knowledge and expertise of the revenue cycle to provide financial and operational performance benefits for healthcare organizations of any size. Our global organization of 4,000 colleagues partners with more than 330 US-based healthcare clients, delivering custom solutions to help solve their business challenges.
We are dedicated to quality service for the medically fragile child. We service our patients based on each child's specific needs to develop their potential through clinical education and technical support. We believe it takes more than health care to
From our humble beginnings in Decatur, GA, in 1955, BioLab today is a leader in providing solutions for recreational and industrial water treatment and home cleaning. Our sales are now in excess of 600 million dollars annually and the stock of our parent
Afferent Pharmaceuticals, Inc. is a leader in the development of novel, selective drugs for the treatment of a range of debilitating neurogenic disorders. These disorders affect millions of patients who suffer from chronic respiratory and urologic sensory pathologies as well as chronic pain, and who have limited, if any, treatment options. These chronic disorders arise when certain nerve fibers become hyper-sensitized as a result of inflammation, distress, infection or tissue injury, and sometimes remain chronically sensitized for months or even years.
Ascendis Pharma is focused on creating drug candidates that are improved versions of existing drugs, yielding more effective, lower-risk drugs with new patent life. Our proprietary TransCon platform is the leading, most versatile transient conjugation technology and is utilized to create clinically superior prodrugs in therapeutic areas characterized by high unmet medical need. TransCon technology creates novel long acting prodrugs of proteins, peptides and small molecules, suitable for either local or systemic treatment. Ascendis Pharma has a diversified and balanced high-value pipeline, including internal programs and partnerships together with market leaders on their key projects.